Skip to main content

Market Overview

KalVista Pharmaceuticals Raises $193.5M Via Equity To Fund KVD900 Development

  • KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising $193.5 million in gross proceeds. Earlier, the company offered 4.5 million shares. The offer price represents a marginal discount of 4% on the last close price of $37.46.
  • Underwriters have an option to purchase up to an additional 806,250 shares.
  • Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.
  • KalVista intends to use the net proceeds to fund the planned Phase 3 trial of KVD900, the planned Phase 2 trial of KVD824, and continued development of KalVista's oral Factor XIIa programs, as well as for general corporate purposes.
  • Recently, the company's stock rallied on positive Phase 2 data from KVD900 that showed reduced use of rescue medication in patients suffering swelling attacks associated with hereditary angioedema.
  • Price Action: KALV stock has gained 2.8% at $38.50 in the premarket trading on the last check Thursday.

Related Articles (KALV)

View Comments and Join the Discussion!

Posted-In: Phase 3 TrialBiotech News Offerings Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at